Drug Information

General Information
Drug ID
DR01288
Drug Name
Palbociclib
Synonyms
LQQ; 571190-30-2; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one; G9ZF61LE7G; HMR-2934; Ibrance; PD 0332991; PD 332991; PD 332991, PD 0332991, PD0332991; PD-0332991; PD-332991; PD0332991; Palbociclib(PD0332991); UNII-G9ZF61LE7G
Drug Type
Small molecular drug
Indication Breast cancer [ICD11: 2C60-2C6Z] Approved [1]
Therapeutic Class
Anticancer Agents
Structure
3D MOL 2D MOL
Formula
C24H29N7O2
Canonical SMILES
CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C
InChI
InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)
InChIKey
AHJRHEGDXFFMBM-UHFFFAOYSA-N
CAS Number
CAS 571190-30-2
Pharmaceutical Properties Molecular Weight 447.5 Topological Polar Surface Area 103
Heavy Atom Count 33 Rotatable Bond Count 5
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 8
XLogP
1.8
PubChem CID
5330286
PubChem SID
8035907 , 11062094 , 11538604 , 12015755 , 14808444 , 17137183 , 39302900 , 46394060 , 57361299 , 78833389 , 99436913 , 103461613 , 103905660 , 103905661 , 113915142 , 121280258 , 124360805 , 124757012 , 125164718 , 126580155 , 126671645 , 126737419 , 131480762 , 134339015 , 134339302 , 134339471 , 134964422 , 135262045 , 135686212 , 135686213 , 135686228 , 135686229 , 136367313 , 136367838 , 136920362 , 137184856 , 137275973 , 141483504 , 143498887 , 144116345 , 152240013 , 152258827 , 152344089 , 160647678 , 162202562 , 164045126 , 172232465 , 172919351 , 177748911 , 178103952
ChEBI ID
CHEBI:85993
TTD Drug ID
D00UZR
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
P-GP Transporter Info P-glycoprotein 1 Substrate [2]
References
1 Palbociclib was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model. J Pharmacol Exp Ther. 2015 Nov;355(2):264-71.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.